[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340059-105":59,"doc-detail-340059-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","advances-in-delivery-systems-for-crisprcas-mediated-cancer-treatment-a-focus-on-viral-vectors-and-extracellular-vesicles","Advances in delivery systems for CRISPR/Cas-mediated cancer treatment - a focus on viral vectors and extracellular vesicles","","CRISPR/Cas delivery systems are positioned as transformative for cancer therapy, with recent work emphasizing extracellular vesicles (EVs) and viral vectors. Engineered EVs, especially exosomes, leverage natural cargo transport to deliver CRISPR/Cas components into tumor cells, suppressing proliferation and improving chemotherapy sensitivity. Viral vectors, notably AAVs and adenoviral vectors, provide strong delivery capacity for both dividing and non-dividing cells, supporting disease modeling and drug discovery. Key remaining barriers include off-target effects and immune responses. Future efforts aim to improve specificity and reduce adverse effects for personalized treatment translation from bench to bedside.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advances-in-delivery-systems-for-crisprcas-mediated-cancer-treatment-a-focus-on-viral-vectors-and-extracellular-vesicles/340059/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advances-in-delivery-systems-for-crisprcas-mediated-cancer-treatment-a-focus-on-viral-vectors-and-extracellular-vesicles/340059.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are extracellular vesicles (EVs) considered promising CRISPR/Cas delivery vehicles for cancer?","Question",{"text":113,"@type":114},"EVs, particularly exosomes, naturally transport cargo and can be engineered to deliver CRISPR/Cas components to tumor cells, where they inhibit proliferation and can enhance chemotherapy sensitivity.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What delivery roles do viral vectors like AAVs and adenoviral vectors play in CRISPR/Cas cancer therapy?",{"text":118,"@type":114},"AAVs have a favorable safety profile and have been used in clinical trials for gene therapy, while adenoviral vectors can infect both dividing and non-dividing cells, supporting broader CRISPR/Cas delivery for modeling and drug discovery.",{"name":120,"@type":111,"acceptedAnswer":121},"What challenges must be addressed to translate CRISPR/Cas-mediated cancer treatments clinically?",{"text":122,"@type":114},"The document highlights off-target effects and immune responses as significant hurdles, and emphasizes refining delivery systems to improve specificity and minimize adverse effects for translation from bench to bedside.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},340059,1790308567,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","TYPE Review  \nPUBLISHED 30 August 2024  \nDOI 10.3389/fimmu.2024.1444437  \nOPEN ACCESS  \nEDITED BY Wenxia He,  \nUniversity of North Carolina at Chapel Hill, United States  \nREVIEWED BY Peiqiang Yan,  \nHarvard Medical School, United States Xiang Sun,  \nSt. Jude Children ’s Research Hospital, United States  \nTao Hou,  \nBeth Israel Deaconess Medical Center and Harvard Medical School, United States  \n*CORRESPONDENCE Jian Li  \n [lijian160@jlu.edu.cn](lijian160@jlu.edu.cn)  \nRECEIVED 05 June 2024  \nACCEPTED 30 July 2024  \nPUBLISHED 30 August 2024  \nCITATION  \nSong Z, Tao Y, Liu Y and Li J (2024) Advancesin delivery systems for CRISPR/Cas-mediated cancer treatment: a focus on viral vectorsand extracellular vesicles.  \nFront. Immunol. 15:1444437 .  \ndoi: 10.3389/fimmu.2024.1444437  \nCOPYRIGHT  \n© 2024 Song, Tao, Liu and Li. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nAdvances in delivery systems for CRISPR/Cas-mediated cancer treatment: a focus on viral vectors and extracellular vesicles  \nZhidu Song 1, Ying Tao 2, Yue Liu 3 and Jian Li 3*  \n1 Department of Ophthalmology, The Second Hospital of Jilin University, Changchun, China,  \n2 Department of Anesthesiology, China-Japan Union Hospital of Jilin University, Changchun, China,  \n3 Department of Emergency and Critical Care, The Second Hospital of Jilin University, Changchun, China  \nThe delivery of CRISPR/Cas systems holds immense potential for revolutionizing cancer treatment, with recent advancements focusing on extracellular vesicles (EVs) and viral vectors. EVs, particularly exosomes, offer promising opportunities for targeted therapy due to their natural cargo transport capabilities. Engineered EVs have shown efficacy in delivering CRISPR/Cas components to tumor cells, resulting in inhibited cancer cell proliferation and enhanced chemotherapy sensitivity. However, challenges such as off-target effects and immune responses remain significant hurdles. Viral vectors, including adeno-associated viruses (AAVs) and adenoviral vectors (AdVs), represent robust delivery platforms for CRISPR/Cas systems. AAVs, known for their safety profile, have already been employed in clinical trials for gene therapy, demonstrating their potential in cancer treatment. AdVs, capable of infecting both dividing and non-dividing cells, offer versatility in CRISPR/Cas delivery for disease modeling and drug discovery. Despite their efficacy, viral vectors present several challenges, including immune responses and off-target effects. Future directions entail refining delivery systems to enhance specificity and minimize adverse effects, heralding personalized and effective CRISPR/Cas-mediated cancer therapies. This article underscores the importance of optimized delivery mechanisms in realizing the full therapeutic potential of CRISPR/Cas technology in oncology. As the field progresses, addressing these challenges will be pivotal for translating CRISPR/Casmediated cancer treatments from bench to bedside.  \nKEYWORDS  \nCRiSPR/Cas, cancer treatment, extracellular vesicle, exosomes, viral vectors  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nCancer is a challenging disease with high mortality rates and significant global concern. Malignant tumors pose a threat to the lives of thousands of human beings, as they are responsible for one out of every six fatalities worldwide (1) . Although there have been numerous noteworthy advancements in the field of cancer therapy, such as chemotherapy, surgery, targeted biotherapy, radiotherapy, and new combination therapies, quality of life and survival ","cbCaiufI73aIhNeS","https://ap.wps.com/l/cbCaiufI73aIhNeS","pdf",4452404,23,"English","# Introduction\n## Cancer challenges and unmet needs\n## Genomic insights for precision oncology\n## Gene editing foundations\n## CRISPR/Cas and delivery platforms","[{\"question\":\"Why are extracellular vesicles (EVs) considered promising CRISPR/Cas delivery vehicles for cancer?\",\"answer\":\"EVs, particularly exosomes, naturally transport cargo and can be engineered to deliver CRISPR/Cas components to tumor cells, where they inhibit proliferation and can enhance chemotherapy sensitivity.\"},{\"question\":\"What delivery roles do viral vectors like AAVs and adenoviral vectors play in CRISPR/Cas cancer therapy?\",\"answer\":\"AAVs have a favorable safety profile and have been used in clinical trials for gene therapy, while adenoviral vectors can infect both dividing and non-dividing cells, supporting broader CRISPR/Cas delivery for modeling and drug discovery.\"},{\"question\":\"What challenges must be addressed to translate CRISPR/Cas-mediated cancer treatments clinically?\",\"answer\":\"The document highlights off-target effects and immune responses as significant hurdles, and emphasizes refining delivery systems to improve specificity and minimize adverse effects for translation from bench to bedside.\"}]","Advances in delivery systems for CRISPR/Cas-mediated cancer treatment - a focus on viral vectors and extracellular vesicles | PDF",1790033985,58]